Genmab — Januar 2019
-
God morgen.
-
Man sidder og håber på besked fra Genmab i sin mail box
-
At JnJ har oplyst at 2mia $ er nået og stor milestone
-
-
Syros also announced today that it has made a portfolio prioritization decision not to pursue further development of SY-1425 in combinationwith daratumumab beyond completion of the ongoing pilot cohort in the Phase 2 trial. https://www.marketwatch.com/press-release/syros-announces-strategic-priorities-and-expected-milestones-2019-01-06
-
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs --> they still believe in BCMAxCD3 https://globenewswire.com/news-release/2019/01/07/1680967/0/en/Sanofi-and-Regeneron-Restructure-Immuno-Oncology-Collaboration-for-Discovery-and-Development-Programs.html#.XDMDpebNEr0.twitter
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind